Market Indices
Sector Heatmap
CRDL — Cardiol Therapeutics Inc. Class A Common Shares
NasdaqCardiol Therapeutics Inc. Class A Common Shares
- O
- 1.60
- H
- 1.64
- L
- 1.40
- V
- 3.58M
CRDL — Latest News & Headlines
9 StoriesFund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan
Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares Stock Titan
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year? Yahoo Finance
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - simplywall.st
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation simplywall.st
Fewer relapses in heart trial push Cardiol Therapeutics (CRDL) to add patients and delay results - Stock Titan
Fewer relapses in heart trial push Cardiol Therapeutics (CRDL) to add patients and delay results Stock Titan
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk - kalkine.ca
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk kalkine.ca
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target - tradingview.com
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target tradingview.com
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares - Kalkine Media
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares Kalkine Media
CRDL Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares as Clinical-Stage Story Holds - Annual Financial Report - siam.in
CRDL Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares as Clinical-Stage Story Holds - Annual Financial Report siam.in
Can Cardiol Therapeutics (TSX:CRDL) Turn Research Into Progress? - Kalkine Media
Can Cardiol Therapeutics (TSX:CRDL) Turn Research Into Progress? Kalkine Media